The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk's Wegovy or similar GLP-1 drugs was $18,507, on average. That represents a 46% jump over the average annual medical cost of $12,695 prior to taking the medication, data provided by pharmacy benefits manager Prime Therapeutics show. The costs for a similar control group of patients not taking the drugs grew by 14% for the same period.
